Mikhail Blagosklonny is recognized for his keen interest and advice on the use of Rapamycin. Rapamycin is a special drug that has shown a great potential of curing cancer which is the reason why Mikhail Blagosklonny has a keen interest in it. He continues to venture in various researches and experiments on it with the hope of finding the breakthrough to cure cancer finally. So far his research work is going well, and he promises positive results soon.
Mikhail Blagosklonny is the chief editor of Cell Cycle and Oncotarget. He is also associated with the editing staff of Cell Death and Differentiation, as well as cancer & therapy biology. This publication releases are involved in writing about the latest developments mainly in the research of various titles which are their names. The publications are systematically stored to show a comprehensive history on the research background undergoing on the topics in question.
Mikhail Blagosklonny has a rich educational background. He attended the First Pavlov State Medical University of St. Petersburg from where he graduated with an M.D in internal medicine. Mikhail also achieved his Ph.D. in Experimental and Cardiology from the same university.
Mikhail Blagosklonny has worked in different medical organizations which mainly deal with cancer research. He has also been a professor in different higher learning institutions. In 2002, he was appointed the professor of medicine at the New York Medical College. After that, he moved to Ordway Research Institute where he was the highest ranked scientist at the Institute. He worked at this institute until 2009 during which he was able to make important discoveries on the relationship between cancer and aging.
In 2009, he was incorporated into Rosewell Park Cancer Institute where he is serving to date as the senior Professor of Oncology. He has diversified his research areas to anti-aging drugs (his main area of focus), cancer, and cancer-related therapies and means by which healthy cells can be guarded against being affected by cancer.
Mikhail Blagosklonny has over 300 articles under his name. The articles are mainly based on cancer and anti-aging research activities. The articles cover clinical investigations, mitosis, tumor growth controllers, cell drug resistance, and apoptosis. He also has articles about chemotherapeutic, cyclotherapy, and on the topic which he is most associated with, oncology. In addition to articles, he has also published books, journals, and various reviews. View Mikhail’s profile on Google Scholar
His relentless efforts in research have greatly contributed to the ease of cancer-related deaths across the world. His major field of study, Oncology, has received recognition from all over the world. He has also helped in advancing ways to reduce cancer-related aging and improve immunity in older adults. His passion for the well-being of human beings and dream of having a cancer-free society drives him in all his undertakings.